Fayhan Alroqi

985 total citations
19 papers, 461 citations indexed

About

Fayhan Alroqi is a scholar working on Infectious Diseases, Immunology and Genetics. According to data from OpenAlex, Fayhan Alroqi has authored 19 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Immunology and 7 papers in Genetics. Recurrent topics in Fayhan Alroqi's work include Immunodeficiency and Autoimmune Disorders (7 papers), SARS-CoV-2 and COVID-19 Research (6 papers) and COVID-19 Clinical Research Studies (6 papers). Fayhan Alroqi is often cited by papers focused on Immunodeficiency and Autoimmune Disorders (7 papers), SARS-CoV-2 and COVID-19 Research (6 papers) and COVID-19 Clinical Research Studies (6 papers). Fayhan Alroqi collaborates with scholars based in Saudi Arabia, United States and Türkiye. Fayhan Alroqi's co-authors include Talal A. Chatila, Louis‐Marie Charbonnier, Tlili Barhoumi, Safa Barış, Ayça Kıykım, Fatmah A. Mansour, Hassan S. Alamri, Clement Ma, Katja G. Weinacht and Thomas A. Fleisher and has published in prestigious journals such as International Journal of Molecular Sciences, Journal of Allergy and Clinical Immunology and Frontiers in Immunology.

In The Last Decade

Fayhan Alroqi

19 papers receiving 457 citations

Peers

Countries citing papers authored by Fayhan Alroqi

Since Specialization

Citations

This map shows the geographic impact of Fayhan Alroqi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fayhan Alroqi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fayhan Alroqi more than expected).

Fields of papers citing papers by Fayhan Alroqi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fayhan Alroqi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fayhan Alroqi. The network helps show where Fayhan Alroqi may publish in the future.

Co-authorship network of co-authors of Fayhan Alroqi

This figure shows the co-authorship network connecting the top 25 collaborators of Fayhan Alroqi. A scholar is included among the top collaborators of Fayhan Alroqi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fayhan Alroqi. Fayhan Alroqi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Novel Presentation of Major Histocompatibility Complex Class II Deficiency with Hemophagocytic Lymphohistiocytosis 2024 ·Journal of Clinical Immunology ·Fayhan Alroqi, (unknown), Abdullah I. Almojali, Tlili Barhoumi, (unknown), (unknown), Mohammed Al Balwi, (unknown)	1
2	Successful treatment of invasive mycobacterium infection with interferon beta in a patient with Interferon-Gamma Receptor 1 deficiency 2024 ·Journal of Infection and Public Health ·Fayhan Alroqi, (unknown), (unknown), (unknown)	1
3	Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines 2024 ·Journal of Infection and Public Health ·Fayhan Alroqi, Tlili Barhoumi, Emad Masuadi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yaseen M. Arabi, Amre Nasr	2
4	Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine 2023 ·Frontiers in Bioengineering and Biotechnology ·Almohanad A. Alkayyal, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sharif Hala, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sharif Hussein Sharif Zein, Fayhan Alroqi, Ahmad Bakur Mahmoud	1
5	SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus 2023 ·Frontiers in Immunology ·Almohanad A. Alkayyal, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Khalid Shah, Fayhan Alroqi, Ahmad Bakur Mahmoud	4
6	S-39-4: PLASMA FROM SARS-COV-2 PATIENTS INDUCES OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION VIA ANGIOTENSIN II TYPE 1 RECEPTOR (AT1R)/P38 MAPK PATHWAY 2023 ·Journal of Hypertension ·Moudhi Almutlaq, Fatmah A. Mansour, Hassan S. Alamri, Fayhan Alroqi, Tlili Barhoumi	1
7	Quantitative proteomics analysis of COVID-19 patients: Fetuin-A and tetranectin as potential modulators of innate immune responses 2023 ·Heliyon ·(unknown), Fatmah A. Mansour, (unknown), (unknown), Feras Almourfi, Hassan S. Alamri, (unknown), Mamoon Rashid, Fayhan Alroqi, Maroua Jalouli, Abdel Halim Harrath, (unknown), Tlili Barhoumi	4
8	Angiotensin II Exaggerates SARS-CoV-2 Specific T-Cell Response in Convalescent Individuals following COVID-19 2022 ·International Journal of Molecular Sciences ·Moudhi Almutlaq, Fatmah A. Mansour, Jahad Alghamdi, (unknown), Abir Alamro, Amani Alghamdi, Hassan S. Alamri, Fayhan Alroqi, Tlili Barhoumi	10
9	Classical and Counter-Regulatory Renin–Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology 2021 ·CJC Open ·Moudhi Almutlaq, Abir Alamro, Fayhan Alroqi, Tlili Barhoumi	16
10	SARS-CoV-2 Coronavirus Spike Protein-Induced Apoptosis, Inflammatory, and Oxidative Stress Responses in THP-1-Like-Macrophages: Potential Role of Angiotensin-Converting Enzyme Inhibitor (Perindopril) 2021 ·Frontiers in Immunology ·Tlili Barhoumi, (unknown), (unknown), Fatmah A. Mansour, Hassan S. Alamri, Maaged Akiel, Fayhan Alroqi, (unknown)	58
11	Seroprevalence of SARS-CoV-2 among high-risk healthcare workers in a MERS-CoV endemic area 2021 ·Journal of Infection and Public Health ·Fayhan Alroqi, Emad Masuadi, Lulwah Alabdan, (unknown), (unknown), (unknown), Tlili Barhoumi, (unknown), Naif Khalaf Alharbi, (unknown), (unknown), Yaseen M. Arabi, Amre Nasr	6
12	Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia 2021 ·Journal of Infection and Public Health ·Naif Khalaf Alharbi, Suliman Alghnam, (unknown), Hind Albalawi, (unknown), (unknown), (unknown), Abdulaziz Alhazmi, Ali Al Qarni, (unknown), Hosam M. Zowawi, (unknown), Jahad Alghamdi, Fayhan Alroqi, Yaseen M. Arabi, Anwar M. Hashem, (unknown), Omar Aldibasi, (unknown)	1
13	Successful hematopoietic stem cell transplant in leukocyte adhesion deficiency type III presenting primarily as malignant infantile osteopetrosis 2020 ·Clinical Immunology ·(unknown), (unknown), Fayhan Alroqi, Reem Mohammed, Abdulrahman Alsultan	8
14	Homozygous truncating NEK10 mutation, associated with primary ciliary dyskinesia: a case report 2020 ·BMC Pulmonary Medicine ·Fuad Al Mutairi, (unknown), (unknown), Fayhan Alroqi, Yusra Alyafee, Muhammad Umair, (unknown), Amjad Khan, (unknown), (unknown), (unknown), Abdulaziz Asiri, (unknown), Majid Alfadhel	13
15	DOCK8 Deficiency Presenting as an IPEX-Like Disorder 2017 ·Journal of Clinical Immunology ·Fayhan Alroqi, Louis‐Marie Charbonnier, Sevgi Keleş, (unknown), (unknown), (unknown), Reem Mohammed, (unknown), Janet Chou, Michel J. Massaad, Raif S. Geha, Zeina Baz, Talal A. Chatila	29
16	Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation 2017 ·Journal of Allergy and Clinical Immunology ·Katja G. Weinacht, Louis‐Marie Charbonnier, Fayhan Alroqi, Ashley Plant, Qi Qiao, Hao Wu, Clement Ma, Troy R. Torgerson, Sergio D. Rosenzweig, Thomas A. Fleisher, Luigi D. Notarangelo, I. Celine Hanson, Lisa R. Forbes, Talal A. Chatila	114
17	Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulation 2017 ·Journal of Allergy and Clinical Immunology ·Fayhan Alroqi, Louis‐Marie Charbonnier, Safa Barış, Ayça Kıykım, Janet Chou, Craig D. Platt, (unknown), Sevgi Keleş, (unknown), Fowzan S. Alkuraya, Michael B. Jordan, Raif S. Geha, Talal A. Chatila	68
18	Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1 2016 ·Journal of Clinical Immunology ·Safa Barış, Fayhan Alroqi, Ayça Kıykım, Elif Karakoç-Aydıner, İsmail Öğülür, Ahmet Özen, Louis‐Marie Charbonnier, Mustafa Bakır, Kaan Boztuǧ, Talal A. Chatila, Işıl Barlan	65
19	T Regulatory Cell Biology in Health and Disease 2016 ·Current Allergy and Asthma Reports ·Fayhan Alroqi, Talal A. Chatila	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact